Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars
Martin Schiestl, chief science officer at Novartis’ Sandoz, on Tuesday explained how the FDA’s draft guidance on statistical approaches to evaluate analytical similarity poses risks …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
